Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$77.11 USD

77.11
6,918,912

+0.99 (1.30%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $77.10 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 248)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific Grows on New Products Amid Recall Issues

Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

    Nabaparna Bhattacharya headshot

    US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch

    Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market

      Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?

      Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Here's Why You Should Buy Boston Scientific (BSX) Stock Now

        Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.

          Boston Scientific (BSX) Beats on Q1 Earnings, Lifts '18 View

          Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q1.

            Boston Scientific (BSX) Beats on Q1 Earnings and Revenues

            Boston Scientific (BSX) has posted impressive results by delivering revenue growth across all segments in Q1.

              Medical Product Stock Earnings Roster for Apr 25: LH & More

              Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

                Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?

                Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.

                  WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes

                  The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.

                    Boston Scientific to Acquire Securus Medical, Boost EP Unit

                    Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                      Boston Scientific to Buy NxThera, Strengthens Urology Arm

                      Even after the NxThera purchase deal culminates, it is not likely to add stimulus to Boston Scientific's (BSX) adjusted earnings per share through 2020 and prove to be accretive only later.

                        Sweta Jaiswal headshot

                        Can Boston Scientific's Pain be a Boon for Edwards & Others?

                        Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.

                          Boston Scientific's Positive Trial Results to Boost EP Unit

                          Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

                            Urmimala Biswas headshot

                            Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

                            According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.

                              3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax

                              Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.

                                Company News For Mar 6, 2018

                                Companies in the news are: YY,XL,BSX,WMT

                                  Boston Scientific Acquires EMcision, Boosts Endoscopy Unit

                                  Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.

                                    Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                    Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                      Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                        Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

                                        Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.

                                          Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

                                          Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.

                                            Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More

                                            As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.

                                              Boston Scientific's (BSX) Millipede Deal Aids MR Business

                                              Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.

                                                Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

                                                Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

                                                  Boston Scientific's Positive SCS Trial Aids Neuromodulation

                                                  Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.